The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia. Issue 2 (February 2022)

• Record Type: Journal Article
• Authors: Li, Chunjie; Zhao, Xinying; He, Yingyi; Li, Ziping; Qian, Jiabi; Zhang, Li; Ye, Qian; Qiu, Fei; Lian, Peng; Qian, Maoxiang; Zhang, Hui
• Is Part Of: Pharmaocogenetics and genomics. Volume 32:Issue 2(2022)
• Publication Date: 2022-02
• Subjects: acute lymphoblastic leukemia -- CDK4/6 inhibitors -- CDKN2A -- inherited variants -- predispose; Pharmacogenetics -- Periodicals; Pharmacogenomics -- Periodicals; Genetic toxicology -- Periodicals; Biomedical genetics -- Periodicals; 615.7
• DOI: 10.1097/FPC.0000000000000451
• Languages: English
• ISSNs: 1744-6872

Abstract

Abstract : Objective: Genetic alterations in CDKN2A tumor suppressor gene on chromosome 9p21 confer a predisposition to childhood acute lymphoblastic leukemia (ALL). Genome-wide association studies have identified missense variants in CDKN2A associated with the development of ALL. This study systematically evaluated the effects of CDKN2A coding variants on ALL risk. Methods: We genotyped the CDKN2A coding region in 308 childhood ALL cases enrolled in CCCG-ALL-2015 clinical trials by Sanger Sequencing. Cell growth assay, cell cycle assay, MTT-based cell toxicity assay, and western blot were performed to assess the CDKN2A coding variants on ALL predisposition. Results: We identified 10 novel exonic germline variants, including 6 missense mutations (p.A21V, p.G45A and p.V115L of p16 INK4A ; p.T31R, p.R90G, and p.R129L of p14 ARF ) and 1 nonsense mutation and 1 heterozygous termination codon mutation in exon 2 (p16 INK4A p.S129X). Functional studies indicate that five novel variants resulted in reduced tumor suppressor activity of p16 INK4A, and increased the susceptibility to the leukemic transformation of hematopoietic progenitor cells. Compared to other variants, p.H142R contributes higher sensitivity to CDK4/6 inhibitors. Conclusion: These findings provide direct insight into the influence of inherited genetic variants at the CDKN2A coding region on the development of ALL and the precise clinical application of CDK4/6 inhibitors. Abstract : Supplemental Digital Content is available in the text.